Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

As Trump's unveiling of Stargate AI boosts names like Nvidia, Palantir and Broadcom, this stock screener highlights 23 ...

Alphabet Inc. consistently surpasses the Rule of 40, with a current score of 42.8, showcasing an excellent balance of growth ...

The company is facing pressure on two fronts—the government and a host of new AI-powered search rivals. It has the capacity to meet both challenges and continue to prosper.

President Donald Trump on Monday revoked former President Joe Biden's comprehensive executive order on artificial ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

As you can see from the chart below, the gains came largely following the quantum computing announcement on Dec. 9. Alphabet shares jumped 5.6% on Dec. 10 and then another 5.5% on Dec. 11 ...

Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) had a solid 2024, with the stock up over 40% as of the time of writing. With that kind of performance, it would be understandable if investors thought it ...

Alphabet (GOOGL 1.60% ... The company's focus for 2025 will clearly be on AI. The CEO displayed a chart showing how its Gemini 1.5 large language model (LLM) is currently in the lead versus ...